.svg)
.svg)
.svg)
.svg){kind=icon}
.svg)
.svg){kind=icon}
.svg)
.svg){kind=icon}
.svg)
.svg){kind=icon}
.svg){kind=icon}
.svg){kind=icon}
Publication date: July 28, 2025
Sartorius AG is a leading German life-science company providing equipment for biotechnology and pharmaceutical research. With a strong position in bioprocess solutions, Sartorius offers both robust growth opportunities and strong financial performance. In this article, we discuss the current stock price, expectations and why Sartorius could be a valuable addition to your investment portfolio. Would you like to receive weekly updates on European equities? Then sign up for our newsletter here and stay informed.
.webp)
- Year of establishment: 1870
- Year added to the DAX 40: 2021
-Highest price ever: €834 September 2021
- Average trading volume: about 8,500 shares per day
- Price performance over the past 12 months: -18,52%
Introduction about the company
Sartorius AG, founded in 1870 and based in Göttingen, Germany. Sartorius AG is a leading supplier of equipment and technology for the biopharmaceutical and laboratory sectors. Through its two divisions, Sartorius supports customers worldwide in research, quality testing and production of biotechnological products such as vaccines and drugs.
Key figures & achievements
In 2024, Sartorius AG achieved sales of €3.38 billion, driven primarily by demand for bioprocess solutions in the pharmaceutical sector. Net profit came in at €180 million, a decrease mainly due to higher costs and challenging market conditions in the biotechnology sector. These cost increases were partly due to strategic investments.
However, net profit improved by nearly 14% in the first half of 2025, driven by more efficient operations and growth in bioprocess solutions. Sartorius' market capitalization stood at about €13.55 billion in July 2025, positioning the company as a mid-sized player within the DAX 40. Over the past 12 months, the share price fell about 18%, partly due to lower investment appetite in the sector and pressure on margins.
History & development
Sartorius AG was founded in 1870 in Göttingen as a fine mechanical workshop specializing in scales. Over the years, the company grew into an international player in biotechnology and laboratory technology. An important step in the modern development of Sartorius was the acquisition of Stedim in 2007, which significantly strengthened the company's position in the bioprocess industry. Since then, Sartorius has focused on innovative solutions for biologics production and has made several strategic acquisitions to expand technology and capacity.
In September 2021, Sartorius was included in the DAX 40 index, confirming the company's increased relevance in the German capital market. In recent years, the focus has been on internationalization, digitalization of production processes and strengthening the offering in single-use technologies, which are becoming increasingly important in the pharmaceutical sector.
Sector & competition
Sartorius operates in the fast-growing biotech and laboratory sector. The company provides specialized equipment and technologies for applications such as cell culture, filtration and fluid management with a strong focus on high-performance single-use systems. In doing so, Sartorius supports the production processes of biotech drugs, vaccines and other advanced therapies.
Competition comes mainly from international players such as Thermo Fisher Scientific, Merck KGaA (life science branch) and Danaher Corporation, which are also active in bioprocess solutions and laboratory technology. Thanks to its innovative product portfolio, scale and global presence, Sartorius manages to maintain a strong position in a specialized market with high barriers to entry.
Influence of Sartorius on the DAX 40
Since its inclusion in the DAX 40 in September 2021, Sartorius represents a modest weighting of 0.38% (measured in December 2024) within the German stock market index. View the composition of the DAX 40 and the weighting of all companies in the DAX 40 here. The stock price becomes sensitive to trends in biotech investments, regulations surrounding drug development and macroeconomic factors such as interest rates and industrial growth. As a technology-oriented company, Sartorius often reacts strongly to sentiment in life sciences and biotech such as IPOs or innovation projects.
Investment analysis & outlook
Sartorius shares have lost about 18% over the past 12 months, partly due to lower sales growth, pressure on margins and a cooling investment appetite in the biotech sector. Nevertheless, there are signs of recovery. In the first half, sales rose 6% to €1.77 billion, while underlying net profit rose almost 14% to €169 million. Sartorius maintained its outlook for 2025, with stable sales growth, especially within the Bioprocess Solutions division.
The sharp spike in 2021, visible in the chart below, came from Sartorius profiting from the corona pandemic. However, this led to a prolonged correction as pandemic-related demand declined. Since then, the stock price has remained under pressure, partly due to uncertainty in the biotech sector. The stock's valuation remains high, with a price-to-earnings ratio above the industry average, making it susceptible to disappointing figures or external shocks.
Still, the growing demand for biologics and single-use technologies offers structural opportunities. Investors who believe in the long-term growth potential of the sector may see the current price level as an attractive entry point. The chart below shows that Sartorius has recently shown signs of bottoming out, which could be a potential turning point for some investors.
News & updates
In July 2025, Sartorius announced additional investments in its global production capacity, particularly in the area of single-use technologies essential for biologics production. In doing so, the company emphasized the importance of scalability and digitization as spearheads for future growth.
In addition, it became clear that demand for repeatable bioprocess products is recovering faster than expected, leading management to confirm earnings expectations for 2025. Sartorius also took steps in the area of sustainability by setting further reduction targets for CO₂ emissions within its supply chain. The company thus continues to profile itself as an innovative and reliable player in a market that increasingly focuses on efficiency and climate responsibility.
Disclaimer: Investing involves risks. Our analysts are not financial advisors. Always consult an advisor when making financial decisions. The information and tips provided on this website are based on our analysts' own insights and experiences. They are therefore for educational purposes only.
.webp)
.webp)
.webp)
.webp)
.webp)
